CombiMatrix Seeks Financial Advisor to Evaluate Sale or Partnership Options | GenomeWeb

By Justin Petrone

CombiMatrix will hire a financial advisor to help it partner with a larger firm that can better support and sell its menu of diagnostics, the firm's top official said last week.

CEO Amit Kumar said during the firm's second-quarter earnings call that CombiMatrix has reached an "inflection point" and is considering deals that could "include the sale of the company or portions of the company."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.